Enfusion, Inc. Executive Severance Policy, adopted on July 19, 2024
Exhibit 10.1
ENFUSION, INC.
EXECUTIVE SEVERANCE POLICY
The Board of Directors (the “Board”) of Enfusion, Inc. (the “Company”) has determined that the Enfusion, Inc. Executive Severance Policy (this “Policy”) should be adopted to reinforce and encourage the continued attention and dedication of the Company’s Covered Executives (as defined in Section 1 hereof) to their assigned duties. Nothing in this Policy shall be construed as creating an express or implied contract of employment and nothing shall alter the “at will” nature of the Covered Executives’ employment with the Company.
1. | Definitions. |
2
2. | Administration of this Policy |
3
All decisions and interpretations of the Administrator shall be conclusive and binding on all persons, including the Company and Covered Executives.
3. | Eligibility |
All Covered Executives who have executed and submitted to the Company a Participation Agreement, and satisfied such other requirements as may be determined by the Administrator, are eligible to participate in this Policy. Following an individual’s designation as a Covered Executive and execution of a Participation Agreement, such individual may not be removed from participating in this Policy as a Covered Executive without his or her written consent.
Notwithstanding the foregoing, if a Covered Executive ceases to be a Covered Executive for any reason other than the termination of such Covered Executive’s employment (i) by the Company without Cause or (ii) by the Covered Executive for Good Reason, then such individual shall immediately cease to be a Covered Executive and shall no longer have any rights pursuant to this Policy. For the avoidance of doubt, a Covered Executive shall not be eligible for severance payments or benefits under this Policy in the event he or she is terminated due to such Covered Executive’s death or disability; provided, however, such Covered Executive shall still be entitled to his or her Accrued Benefits.
4. | Severance Payments and Benefits |
If the employment of a Covered Executive is terminated either by the Company without Cause or by the resignation of the Covered Executive for Good Reason, then, in addition to the Accrued Benefits, the Covered Executive shall be eligible to receive the benefits described within this Section 4. These benefits are subject to the Covered Executive’s execution of a Separation Agreement and Release, and the Separation Agreement and Release becoming irrevocable, all within the time frame set forth in the Separation Agreement and Release but in no event to exceed 60 days from the Date of Termination.
4
The amounts payable under Section 4(a) shall be paid out in single lump sum within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as “non-qualified deferred compensation” within the meaning of Section 409A of the Code, shall begin to be paid in the second calendar year by the last day of such 60-day period. The amounts payable under Section 4(b), to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months, commencing within 60 days, after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as “non-qualified deferred compensation” within the meaning of Section 409A of the Code, shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination.
5. | General Terms and Conditions. |
5
6
7
(i) if the Covered Executive is not the Chief Executive Officer of the Company:
Attention: Chief Executive Officer
Enfusion, Inc.
125 South Clark Street, Suite 750,
Chicago, IL 60603
8
with a copy to:
Attention: General Counsel
Enfusion, Inc.
125 South Clark Street, Suite 750,
Chicago, IL 60603
(ii) if the Covered Executive is the Chief Executive Officer of the Company:
Attention: Chair of the Board of Directors
Enfusion, Inc.
125 South Clark Street, Suite 750,
Chicago, IL 60603
with a copy to:
Attention: General Counsel
Enfusion, Inc.
125 South Clark Street, Suite 750,
Chicago, IL 60603
9
DATE ADOPTED BY THE BOARD: July 19, 2024
10